Clinical

Latest News


Latest Videos


CME Content


More News

Video 2 - "SunRISe-1: Examining Combination Therapy for HR NMIBC"

1) A medical urologist discusses the rationale and design of the SunRISe-1 phase 2 trial, which evaluates the combination of intravesical TAR-200 and systemic cetrelimab, as well as the TAR-200 and cetrelimab monotherapy arms, in patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (HR NMIBC), focusing on key efficacy and safety endpoints.

Video 1 - "Comparing Long-Term Efficacy of Bladder-Preserving Therapies for NMIBC "

Neal Shore, MD, FACS, discuss the key efficacy outcomes reported for nadofaragene firadenovec (ADSTILADRIN) in the phase 3 trial for patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) and compare these long-term results to other bladder-preserving therapies in this population.

what we're reading logo

The CDC has asked local and state health officials to maintain peak-season flu surveillance operation levels over the summer to watch for any signs of human-to-human spread of the H5N1 bird flu virus; the drug industry’s top lobbying group faced thorough questioning at a Senate Judiciary Committee hearing about the impact of patent system abuse on high prescription drug prices; FDA staff reviewers have raised concerns that Guardant Health’s colorectal cancer (CRC) blood test may fail to detect precancerous tumors.

Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo